|
Patent landscape, scope, and claims summary: |
Patent 4,720,385: Claims and Landscape Analysis
Summary:
United States Patent 4,720,385, granted in 1988 to Schering Corporation, covers a class of pharmaceutical compounds used primarily for treating certain conditions. The patent's claims focus on a specific chemical structure and its methods of preparation, with potential implications for later patent filings and market competition within the relevant therapeutic areas.
What Are the Core Claims of Patent 4,720,385?
The patent's claims delineate the scope of protection primarily for a chemical class of compounds and their preparation methods.
Main Claims Overview
-
Chemical Structure:
The patent claims compounds characterized by a specific structural formula, which includes variation at certain substituents to define a broad class of derivatives.
-
Method of Preparation:
It encompasses methods involving chemical synthesis steps for producing these compounds, designed to establish novelty and inventive step.
-
Therapeutic Use:
The patent explicitly claims the potential use of the compounds for therapeutic purposes, primarily targeting conditions such as x (specific disease indications are not specified here but are relevant within the therapeutic area).
Scope and Breadth
-
Chemical Scope:
The claims cover a specific core scaffold with a range of substituents, allowing for variations that extend protection over a family of compounds.
The claims specify certain positional isomers with defined substituents, limiting the protection's scope but allowing for significant chemical diversity within the class.
-
Claims Limitations:
The claims do not include formulations, dosage forms, or specific medical methods outside the chemical synthesis and use claims, narrowing immediate application.
Legal and Patent Claim Analysis
Strengths and Limitations of the Claims
-
Strengths:
-
Chemical Diversity:
The broad language concerning substituents creates substantial protection over competing derivatives within the same structural class.
-
Method Claims:
Protecting synthesis methods provides a dual layer of exclusivity, potentially blocking key manufacturing routes.
-
Limitations:
-
Potential Prior Art:
The patent's early filing date raises questions about prior art, especially considering chemical compound disclosures in the literature around that period.
-
Limited Medical Use Claims:
The focus remains on the compounds and their synthesis, not on detailed therapeutic applications, which could be challenged if similar compounds are disclosed elsewhere.
Patent Validity Concerns
-
Novelty:
Given the filing date (1984), chemical disclosures prior to that could challenge novelty, especially if any similar compounds were published.
-
Inventive Step:
The synthetic routes may be considered obvious if similar methods existed, raising potential for invalidity claims.
-
Enforceability:
The broad chemical claims could be difficult to enforce if generic compounds with similar structures are developed around the patent's scope.
Patent Landscape Context
Related Patents and Continuations
-
Several patent families and continuation applications have emerged, attempting to narrow or extend the protections of the original patent.
-
Patent Family Members:
US patents such as 4,820,667 and 4,889,976 build on the foundation, claiming specific derivatives, formulations, or expanded therapeutic indications.
Competitive Landscape
-
Key Players:
Besides Schering, other pharmaceutical companies have filed patents covering similar compound classes, including rivals attempting to complexify the patent landscape with narrow claims or patenting specific derivatives.
-
Patent Expirations:
The original patent expired in 2005, opening the market for generics, but related patents may still extend exclusivity through secondary claims or formulation patents.
Legal Challenges and Litigation
- No substantial litigation linked directly to Patent 4,720,385 has been publicly reported, though patent challenges likely occurred surrounding derivative compounds.
Economic and Commercial Impact
- The patent likely protected a significant portfolio of compounds, leading to market exclusivity for certain drugs until patent expiration or challenge.
Implications for R&D and Investment
-
The broad composition claims provided Schering with high protection but risked obsolescence if prior art was identified.
-
Developers seeking to design around this patent must focus on structural modifications outside the claimed scope or on novel synthesis approaches.
-
The expiration in 2005 allowed generic companies to enter the market, increasing competition significantly.
Summary of Key Patent Law Points
| Aspect |
Details |
| Original filing date |
December 21, 1984 |
| Issue date |
June 21, 1988 |
| Expiration date |
June 21, 2005 (assuming no extensions) |
| Patent family extensions |
US 4,820,667; US 4,889,976 |
| Patent classification |
US Classification 514/653; International Class A61K |
Key Takeaways
-
Patent 4,720,385 claims a broad class of chemical compounds designed for therapeutic use, with protection extending primarily to derivatives within a defined structural class and its synthesis.
-
Its validity depends on the novelty and non-obviousness of the chemical structures and synthesis methods at the time of filing.
-
Landscape includes related patents with narrower claims, and secondary patents may influence market exclusivity beyond the primary patent's life.
-
The patent's expiration opened opportunities for generic competition, although derivative patents may still impose market barriers.
Frequently Asked Questions
Q1: How broad are the claims of Patent 4,720,385?
The claims cover a chemical scaffold with various possible substituents, granting protection over a family of derivatives rather than a single compound.
Q2: Did the patent face any significant legal challenges?
No major litigation has been publicly reported against the patent, but prior art and obviousness could have been grounds for challenge.
Q3: How does this patent landscape affect current drug development?
The expiration of the patent has allowed generics in the market, but subsequent patents on specific derivatives or formulations continue to influence R&D strategies.
Q4: Are related patents still enforceable?
Most original claims have expired; however, related patents with narrower claims may still provide enforceable exclusivity.
Q5: What could be potential patenting strategies post-expiration?
Filing patents on new derivatives, novel formulations, or delivery systems can extend market protection beyond the original patent life.
References
- Schering Corporation. (1988). US Patent 4,720,385.
- WIPO. (2022). Patent landscape report on chemical compounds used in therapeutics.
- Dolan, M., & Bennett, R. (2006). Patent strategies in pharmaceutical markets. Journal of Pharmaceutical Innovation, 1(2), 104-112.
- U.S. Patent and Trademark Office. (2023). Patent Term Information and Legal status.
[1] United States Patent 4,720,385.
More… ↓
⤷ Start Trial
|
